Literature DB >> 15931516

Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.

Sean J Colloby1, E David Williams, David J Burn, Jim J Lloyd, Ian G McKeith, John T O'Brien.   

Abstract

PURPOSE: The objective of this study was to investigate the rate of progression of nigrostriatal dopaminergic loss in subjects with dementia with Lewy bodies (DLB), Parkinson's disease (PD) and PD with dementia (PDD) using serial 123I-FP-CIT SPECT imaging. We hypothesised that striatal rates of decline in patients would be greater than in controls, and that DLB and PDD would show similar rates, reflecting the similarity in neurobiological mechanisms of dopaminergic loss between the two disorders.
METHODS: We studied 20 patients with DLB, 20 with PD, 15 with PDD and 22 healthy age-matched controls. Semi-automated region of interest (ROI) analysis was performed on both baseline and repeat scans for each subject and mean striatal uptake ratios (caudate, anterior and posterior putamen) were calculated.
RESULTS: Rates of decline in striatal binding between groups were assessed using ANCOVA. Significant differences between patients and controls were observed in caudate (DLB, PD, PDD, p< or =0.01), anterior putamen (DLB, PDD, p< or =0.05; PD, p=0.07) and posterior putamen (DLB, PD, PDD, p<0.006). Rates of decline were similar between DLB, PD and PDD.
CONCLUSION: In conclusion, this is the first study to show that significant progressive dopaminergic loss occurs in DLB and PDD using serial 123I-FP-CIT SPECT. Dementia severity and motor impairment were correlated with decline, suggesting that dopaminergic loss may play an important role in cognitive as well as motor features.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931516     DOI: 10.1007/s00259-005-1830-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

1.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

2.  Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Authors:  R B Innis; K L Marek; K Sheff; S Zoghbi; J Castronuovo; A Feigin; J P Seibyl
Journal:  Mov Disord       Date:  1999-05       Impact factor: 10.338

Review 3.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

4.  Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT.

Authors:  W Staffen; A Mair; J Unterrainer; E Trinka; G Ladurner
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

5.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

6.  CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia.

Authors:  M Roth; E Tym; C Q Mountjoy; F A Huppert; H Hendrie; S Verma; R Goddard
Journal:  Br J Psychiatry       Date:  1986-12       Impact factor: 9.319

7.  L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia.

Authors:  S B Bonelli; G Ransmayr; M Steffelbauer; T Lukas; C Lampl; M Deibl
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

8.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

9.  Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study.

Authors:  David J Burn; Elise N Rowan; Thais Minett; Jonathon Sanders; Pat Myint; Jonathon Richardson; Alan Thomas; Jane Newby; Jenny Reid; John T O'Brien; Ian G McKeith
Journal:  Mov Disord       Date:  2003-08       Impact factor: 10.338

10.  Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.

Authors:  Enrique Noe; Karen Marder; Karen L Bell; Diane M Jacobs; Jennifer J Manly; Yaakov Stern
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338

View more
  16 in total

1.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

Review 2.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 3.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

4.  Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder.

Authors:  Zhemin Huang; Chengfeng Jiang; Ling Li; Qian Xu; Jingjie Ge; Ming Li; Yihui Guan; Jianjun Wu; Jian Wang; Chuantao Zuo; Huan Yu; Ping Wu
Journal:  J Cereb Blood Flow Metab       Date:  2019-02-10       Impact factor: 6.200

5.  Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis.

Authors:  Teresa M Karrer; Anika K Josef; Rui Mata; Evan D Morris; Gregory R Samanez-Larkin
Journal:  Neurobiol Aging       Date:  2017-05-12       Impact factor: 4.673

6.  Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia.

Authors:  E R Bychkov; V V Gurevich; J N Joyce; J L Benovic; E V Gurevich
Journal:  Neurobiol Aging       Date:  2006-11-27       Impact factor: 4.673

7.  Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease.

Authors:  A Lokkegaard; L M Werdelin; L Regeur; M Karlsborg; S R Jensen; E Brødsgaard; F F Madsen; M N Lonsdale; L Friberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-10       Impact factor: 9.236

8.  Differential diagnosis of dementia with Lewy Bodies and Alzheimer Disease using combined MR imaging and brain perfusion single-photon emission tomography.

Authors:  H Goto; K Ishii; T Uemura; N Miyamoto; T Yoshikawa; K Shimada; S Ohkawa
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

9.  Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging study.

Authors:  Richard F Seegal; Kenneth L Marek; John P Seibyl; Danna L Jennings; Eric S Molho; Donald S Higgins; Stewart A Factor; Edward F Fitzgerald; Elaine A Hills; Susan A Korrick; Mary S Wolff; Richard F Haase; Andrew C Todd; Patrick Parsons; Robert J McCaffrey
Journal:  Neurobiol Dis       Date:  2010-01-20       Impact factor: 5.996

10.  The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies.

Authors:  Angelo Antonini
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.